

Global clinical development pipeline

Updated: 5 Nov 2025

Phase 1				Phase 2	Phase 3	Accepted submissions Major markets (US, CN, EU, JP)
Sonrotoclax BCL2i 101 B-cell malignancies 102 B-cell malignancies 103 AML/MDS 105 R/R MM t(11;14) 108 Dose ramp-up	BG-75202 101 BC and solid tumors**	KAT6A/Bi BGB-58067 MTA Coop. PRMT5i 101 Lung and Solid Tumors	BG-C137 FGFR2b ADC 101 GI cancers	Sonrotoclax BCL2i 201 R/R MCL 203 R/R WM 204 TN CLL/SLL	Zanubrutinib BTKi 306 TN MCL 308 R/R MZL, R/R FL 309 pMN	Sonrotoclax BCL2i 201 R/R MCL (CN) 202 R/R CLL (CN)
BGB-16673 BTK CDAC 101 B-cell malignancies 102 B-cell malignancies 104 B-cell malignancies 107 Chronic spontaneous urticaria	BG-60366 EGFR CDAC 101 Lung cancers	BG-89894³ MAT2Ai 101 Lung and Solid Tumors	BGB-B3227 MUC1 x CD16A BsAb 101 Solid tumors	BGB-16673 BTK CDAC 101 R/R CLL and R/R WM 102 R/R CLL	Sonrotoclax BCL2i 301 TN CLL 302 R/R MCL 303 R/R CLL/SLL	Tarlatamab⁴ DLL3 x CD3 BiTE[®] 20230273 3L+ SCLC (CN) 20210004 2L SCLC (CN)
BG-71332 BTki + BCL2i 101 Relative bioavailability	BG-T187 EGFR xMETx METTsAb 101 Lung and GI Cancers	BGB-B2033 GPC3 x 4-1BB BsAb 101 Solid tumors	Xaluritamig⁴ STEAP1xCD3 XmAb[®] 20180146 mCRPC	Blinatumomab⁴ CD19 x CD3 BiTE[®] 20180257 R/R B-ALL SubQ, MRD+	BGB-16673 BTK CDAC 302 R/R CLL 303 R/R CLL/SLL 304 R/R CLL/SLL (vs. Pirta)	Tiselizumab PD-1 mAb 305 1L GC (JP) - Alternate dosing Q6W (U.S.)
BGB-21447 BCL2i 101 B-cell malignancies 102 HR+ Breast cancer	BGB-C354 B7-H3 ADC 101 Solid tumors	BGB-R046 IL-15 prodrug 101 Solid tumors/pan-tumor	BGB-45035 IRAK4 CDAC 101 Immunology and Inflammation	Tarlatamab⁴ DLL3 x CD3 BiTE[®] 20240092 2L SCLC (Alt dosing)	Pamiparib PARPi 302 2L PSOC Mtx	
BGB-43395 CDK4i 101/102 BC and solid tumors	BGB-26808 HPK1i 101 Solid tumors/pan-tumor	BGB-C0902 EGFR xMETx MET ADC 101 Lung and GI cancers**		BGB-45035 IRAK4 CDAC 201 Rheumatoid Arthritis	Tarlatamab⁴ DLL3 x CD3 BiTE[®] 20200041 1L ES-SCLC MTx 20240178 1L ES-SCLC Ind. and MTx 20230016 LS-SCLC	
BG-C9074¹ B7-H4 ADC 101 BC and solid tumors	Tarlatamab⁴ DLL3 x CD3 BiTE[®] 20240124 2L+ SCLC (+B7-H3) 20230298 2L+ SCLC SubQ**				Zanidatamab⁵ HER2 BsAb 301 1L HER2+ GEA	
BG-68501² CDK2i 101 BC and solid tumors	BG-C0902 EGFR xMETx MET ADC 101 Lung and GI cancers**				Tiselizumab PD-1 mAb 310 1L UBC 316 SubQ	
BGB-A3055 CCR8 mAb 101 Solid tumors/pan-tumor	BGB-53038 Pan-KRAsi 101 Lung and GI cancers					
BGB-B455 CLDN 6 x CD3 BsAb 101 Gyn. and solid tumors	BG-C477 CEA ADC 101 Lung and GI cancers					

- Hematology
- Lung
- Breast / Gynecological
- Gastrointestinal
- Other cancers
- Immunology and Inflammation

¹ DualityBio collaboration, ² Ensem collaboration, ³ CSPC collaboration, ⁴ Amgen collaboration, ⁵ Zymeworks/Jazz collaboration
Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details
** Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

